Senzer's Respiratory Cannabinoid Device Notches Up Another Design Award

London (ots/PRNewswire) - Senzer's pharmaceutical cannabinoid device has won
another major design award, with the German Design Council commending the unique
inhaler for having 'a clear modern design that perfectly combines ergonomics and
functionality'.

The award is the third design success for Senzer's Class IIa Medical Device,
which is breath-activated and delivers a precise dose of pharmaceutical
cannabinoids, and has been used in a clinical setting for treating side effects
linked to cancer treatment. Senzer believes its patented and unique platform --
described as Systemic inhaled Drug Delivery (SiDD) -- holds considerable
advantages over other means of cannabinoid intake, such as oral, as well as
other respiratory offerings, such as vaping.

The German Design Council said the criteria for its award was for 'projects that
truly represent pioneering contributions to the German and international design
landscape.' Senzer won the prize for Excellent Product Design in the category of
'Medical, Rehabilitation and Health Care'

'The pharmaceutical inhaler features a clear, modern design that perfectly
combines ergonomics and functionality,' a statement by the jury read. 'The
compact inhaler is intuitive and convenient to use and can also be used on the
move.'

The award description explained that the device 'is the first pharmaceutical
multi-use inhaler for systemic drug delivery. It is capable of quickly and
effectively delivering pharmaceuticals into the bloodstream for the relief of
cancer treatment side effects. SiDD's unique micro-engineered design is
optimised for deep lung drug deliver and systemic effect. Clinical trials showed
the SiDD provides systemic delivery in two minutes, compared with 1.5 hours for
a tablet.'

The latest success follows on awards earlier this year, from the Hannover-based
iF International Forum Design GmbH, the world's oldest independent design
organisation, and the Chicago-based GOOD DESIGN ® Awards, in which the inhaler
was recognised for 'revolutionising the delivery of systemic medications through
the lungs.'

'The validation from such a prestigious body as the German Design Council again
underlines that we have a unique breakthrough product, engineered to address the
concerns of those who may benefit from cannabinoid treatment,' said Paul Young,
Head of Design & Engineering. 'It also reflects the extensive R&D work we have
done to date, which is a vital foundation now that we are moving into full
commercialisation.'

Senzer recently received approval of a CE mark for its device, and has plans to
launch in the European unlicensed medicine sector, known as Specials. The
Company believes the device has numerous applications in mainstream consumer
healthcare, as the SiDD platform is capable of delivering many varieties and
formulations of cannabinoids, from both botanical and synthetic sources.

https://www.german-design-award.com/en/the-winners/gallery/detail/28749-systemic
-inhaled-delivery-device.html

About SENZER

SENZER Ltd. is a U.K.-based inhalation technology company
specializing in the development and commercialization of therapeutic
delivery systems of cannabinoid products, and it is developing a
pipeline of inhalation and delivery products to meet unmet medical
needs. Senzer's platform is based around a patented device that
allows swift and effective inhaled delivery of cannabinoids, as well
as other active pharmaceuticals.

www.senzer.com

Logo - https://mma.prnewswire.com/media/803998/Senzer_Logo.jpg

Contact:
Samantha Simpson
+44(0)203-457-0453
press@senzer.com

Additional content: https://www.presseportal.de/pm/131299/4448117
OTS: Senzer Limited

Original-Content von: Senzer Limited, übermittelt durch news aktuell